History
Congress created the 503B outsourcing facility category in the Drug Quality and Security Act, enacted on November 27, 2013. The law followed a 2012 fungal meningitis outbreak linked to contaminated injections from a compounding pharmacy. Registration as an outsourcing facility is voluntary.
Requirements
A 503B outsourcing facility registers with the FDA and must meet CGMP, the same type of quality standard used for drug manufacturing. The FDA inspects outsourcing facilities on a risk-based schedule. Each facility must report adverse events and send the FDA information about the products it compounds.
Unlike a 503A pharmacy, a 503B outsourcing facility does not need a prescription for each patient. It can fill patient-specific prescriptions or supply hospitals and clinics with office stock on a provider order.
Active ingredients
A 503B outsourcing facility can compound from bulk drug substances only if the substance is on the FDA 503B bulks list, or if the drug is on the FDA drug shortage list at the time it is compounded, distributed and dispensed. The facility also may not make drugs that are essentially copies of an approved drug.
Products from a 503B outsourcing facility carry labels that state the drug is compounded, and they are not FDA-approved. Many hospitals buy ready-to-use injections, such as prefilled syringes, from outsourcing facilities instead of preparing them on site.
GLP-1 medicines
While semaglutide and tirzepatide injections were on the shortage list, 503B outsourcing facilities could make them from bulk ingredients. After the shortages were resolved, the FDA set end dates of March 19, 2025 for tirzepatide and May 22, 2025 for semaglutide. In its April 1, 2026 update, the FDA said neither drug was on the 503B bulks list or the shortage list.
Since then, compounded GLP-1 medicines sold through online programs come mainly from 503A pharmacies. See compounding pharmacy and the compounded vs brand page.
Timeline
- November 27, 2013Drug Quality and Security Act creates outsourcing facilities.
- March 19, 2025End of 503B shortage-based compounding of tirzepatide.
- May 22, 2025End of 503B shortage-based compounding of semaglutide.
Compare compounded and brand programs
See also
References
- FDA: Human drug compounding laws. fda.gov
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). fda.gov
- FDA: Human drug compounding. fda.gov
Last updated . Category: Pharmacy & compounding. Browse all 38 WikiTelehealth entries.